Hi everyone,
I am actually type 2 but as I live in Israel I have been the following the fortunes of a biopharmaceutical company over here call Andromeda Biotechology, which has focused exclusively on the development of a therapy for type 1 diabetes. Its lead product, DiaPep 277 is in Phase III trials so I thought it would be only a matter of time before it attracted the interest of one of the major international groups. And sure enough, last Thursday a report appeared on a local news outlet confirming what I had expected all along. Andromeda has been acquired by the US company Hyperion Therapeutics.
This takes the development of what I think is the first medication specifically for type 1 sufferers one step closer to becoming commercially available and hopefully many more similar items will follow. So all, in all, this is a very important breakthrough. The link to the article appears below.
http://www.globes.co.il/en/article-hyperion-acquires-andromeda-for-up-to-570m-1000933645
best,
Ellis79
I am actually type 2 but as I live in Israel I have been the following the fortunes of a biopharmaceutical company over here call Andromeda Biotechology, which has focused exclusively on the development of a therapy for type 1 diabetes. Its lead product, DiaPep 277 is in Phase III trials so I thought it would be only a matter of time before it attracted the interest of one of the major international groups. And sure enough, last Thursday a report appeared on a local news outlet confirming what I had expected all along. Andromeda has been acquired by the US company Hyperion Therapeutics.
This takes the development of what I think is the first medication specifically for type 1 sufferers one step closer to becoming commercially available and hopefully many more similar items will follow. So all, in all, this is a very important breakthrough. The link to the article appears below.
http://www.globes.co.il/en/article-hyperion-acquires-andromeda-for-up-to-570m-1000933645
best,
Ellis79
